Statement: Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR).
Primary_evidence: Outcome Measurement:    Percentage of Participants With Overall Response Rate (ORR)   Overall Response Rate (ORR) was defined as the proportion of patients whose best overall response was either complete response (CR) or partial response (PR) according to RECIST 1.0 for target lesions and assessed by CT: Complete Response (CR), disappearance of all target lesions for a period of at least one month; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (ORR) = CR + PR. Only descriptive statistics.   Time frame: From the date of randomization until the date of the first documented disease progression or date of death from any cause whichever came first, assessed for approximately 15 months Results 1:    Arm/Group Title: Everolimus + Letrozole   Arm/Group Description: All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.   Overall Number of Participants Analyzed: 43   Measure Type: Number   Unit of Measure: Percentage of Participants  37.2